News

Purpose: To evaluate the effect of intravitreal bevacizumab (Avastin) injections on visual acuity (VA) and foveal retinal thickness in patients with macular oedema secondary to branch retinal vein ...
The two drugs, accordingly, inhibit the process of neovascularisation. Ranibizumab is approved to treat neovascular AMD by injection into the eye (intravitreal injection), while bevacizumab is ...
Studies have shown that erlotinib combined with bevacizumab could bring progression-free ... progression-free survival (PFS), CNS objective response rate (ORR). The second end point was to explore the ...
Bevacizumab combined with fluorouracil-based chemotherapy has become the standard for first-line treatment of metastatic colorectal cancer. It may prove useful for other tumors as well.
This finding shed light on a long-standing mystery: the mechanism of action of inhalational anesthetics, which has remained only partially understood for nearly 180 years.
BioDlink's Bevacizumab Injection has been granted marketing authorization by Nigeria's National Agency for Food and Drug Administration and Control (NAFDAC), following GMP certifications in Brazil ...
The researchers evaluated alectinib and bevacizumab in the phase 2 ALEK-B trial (NCT03779191), which included 41 patients with treatment-naïve, metastatic, ALK-rearranged NSCLC. The patients’ median ...
Epilepsy is a long-lasting neurological condition distinguished by recurring seizures, and related to oxidative stress and inflammation. This study investigates the effects of long non-coding RNA LBX2 ...
The mechanism of action (MoA) of a clickable fatty acid analogue 8-(2-cyclobuten-1-yl)octanoic acid (DA-CB) has been investigated for the first time. Proteomics, metabolomics, and lipidomics were ...
We systematically searched MEDLINE, Cochrane, EMBASE, and Web of Science for randomized controlled trials published until November 2016 that assessed patients with cancer treated with or without ...
Methods: AGO-OVAR 2.29 is a randomized (1:1), double blinded, phase III trial evaluating the efficacy and safety of atezolizumab plus bevacizumab and chemotherapy (weekly paclitaxel or pegylated ...
ISELIN, N.J., June 10, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment ...